Kenvue /$KVUE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Kenvue
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.
Ticker
$KVUE
Sector
Primary listing
NYSE
Employees
22,000
Headquarters
Website
Kenvue Metrics
BasicAdvanced
$32B
22.64
$0.75
0.66
$0.83
4.90%
Price and volume
Market cap
$32B
Beta
0.66
52-week high
$25.17
52-week low
$14.02
Average daily volume
46M
Dividend rate
$0.83
Financial strength
Current ratio
0.98
Quick ratio
0.577
Long term debt to equity
67.312
Total debt to equity
85.659
Dividend payout ratio (TTM)
109.98%
Interest coverage (TTM)
6.93%
Profitability
EBITDA (TTM)
3,256
Gross margin (TTM)
58.33%
Net profit margin (TTM)
9.55%
Operating margin (TTM)
17.91%
Effective tax rate (TTM)
25.29%
Revenue per employee (TTM)
$680,000
Management effectiveness
Return on assets (TTM)
6.20%
Return on equity (TTM)
13.47%
Valuation
Price to earnings (TTM)
22.642
Price to revenue (TTM)
2.162
Price to book
3.05
Price to tangible book (TTM)
-4.31
Price to free cash flow (TTM)
19.869
Free cash flow yield (TTM)
5.03%
Free cash flow per share (TTM)
0.852
Dividend yield (TTM)
4.87%
Forward dividend yield
4.90%
Growth
Revenue change (TTM)
-2.93%
Earnings per share change (TTM)
35.31%
3-year revenue growth (CAGR)
0.20%
3-year earnings per share growth (CAGR)
-15.28%
What the Analysts think about Kenvue
Analyst ratings (Buy, Hold, Sell) for Kenvue stock.
Kenvue Financial Performance
Revenues and expenses
Kenvue Earnings Performance
Company profitability
Kenvue News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kenvue stock?
Kenvue (KVUE) has a market cap of $32B as of December 07, 2025.
What is the P/E ratio for Kenvue stock?
The price to earnings (P/E) ratio for Kenvue (KVUE) stock is 22.64 as of December 07, 2025.
Does Kenvue stock pay dividends?
Yes, the Kenvue (KVUE) stock pays dividends to shareholders. As of December 07, 2025, the dividend rate is $0.825 and the yield is 4.9%. Kenvue has a payout ratio of 109.98% on a trailing twelve-month basis.
When is the next Kenvue dividend payment date?
The next Kenvue (KVUE) dividend payment date is unconfirmed.
What is the beta indicator for Kenvue ?
Kenvue (KVUE) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.